Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low‐grade gliomas. Issue 5 (2nd March 2022)

• Record Type: Journal Article
• Authors: da Costa, Marcos Devanir; Watanabe, Rodrigo Akira; Soares, Carolina Torres; Dassi, Natalia; Dastoli, Patricia Alessandra; Nicácio, Jardel Mendonça; Cappellano, Andrea Maria; Silva, Nasjla Saba; Cavalheiro, Sergio
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-02
• Subjects: bevacizumab -- optic pathway glioma -- suprasellar low‐grade glioma; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29637
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Optic pathway gliomas (OPG) can cause elevated cerebrospinal fluid (CSF) protein concentrations. We report on two patients with suprasellar low‐grade gliomas and high CSF protein levels (590 and 551 mg/dl) that precluded shunt implantation. After two and three doses of bevacizumab, respectively, the levels dropped dramatically to 191 and 178 mg/dl, respectively. Bevacizumab treatment was associated with a decrease in CSF protein level, allowing successful shunt placement. Our results are consistent with the pharmacological mechanism of bevacizumab, which decreases protein leakage from blood vessels to the ventricles.